[ 1 ] Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system[J]. Acta Neuropathol, 2007, 114(2): 97-109.
[2]
[ 2 ] Burger PC, Scheithauer BW, Paulus W, et al. Pilocytic astrocytoma[M]//Kleihues P, Cavenee WK. Pathology and genetics of tumours of the nervous system. Lyon: IARC Press, 2000: 45-51.
[3]
[ 3 ] Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med, 2005, 352(10): 987-996.
[4]
[ 4 ] Wen PY, Kesari S. Malignant gliomas in adults[J]. N Engl J Med, 2008, 359(5): 492-507.
[5]
[ 5 ] Yamanaka R. Moleeular-targeted therapy for malignantglioma[J]. Brain Nerve, 2009, 61(2): 177-178.
[6]
[ 6 ] Parsons DW. An integrated genomic analysis of human glioblastoma multiforme[J]. Science, 2008, 321(5897): 1807-1812.
[7]
[ 7 ] Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas[J]. N Engl J Med, 2009, 360(8): 765-773.
[8]
[ 8 ] Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas[J]. Am J Pathol, 2009, 174(4): 1149-1153.
[9]
[ 9 ] Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors[J]. Acta Neuropathol, 2008, 116(6): 597-602.
[10]
Bleeker FE, Lamba S, Leenstra S, et al. IDH1 mutations at residue p.R132(IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors[J]. Hum Mutat, 2009, 30(1): 7-11.
[11]
Sonoda Y, Kumabe T, Nakamura T, et al. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients[J]. Cancer Sci, 2009, 100(10): 1996-1998.
Heller P, Best WR, Nelson RB, et al. Clinical implications of sickle-cell trait and glucose-6-phosphate dehydrogenase deficiency in hospitalized black male patients[J]. N Engl J Med, 1979, 300(18): 1001-1005.
[15]
Lee SM, Koh HJ, Park DC, et al. Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells[J]. Free Radic Biol Med, 2002, 32(11): 1185-1196.
[16]
Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate[J]. Nature, 2010, 465(7300): 966.
[17]
Xu X, Zhao J, Xu Z, et al. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity[J]. J Biol Chem, 2004, 279(32): 33946-33957.
[18]
Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas[J]. Neuro Oncol, 2009, 11(4): 341-347.
[19]
Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha[J]. Science, 2009, 324(5924): 261-265.
[20]
Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases[J]. Cancer Cell, 2011, 19(1): 17-30.
[21]
Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas[J]. Acta Neuropathol, 2010, 120(6): 707-718.
[22]
Christensen BC, Smith AA, Zheng S, et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma[J]. J Natl Cancer Inst, 2011, 103(2): 143-153.
[23]
Mellai M, Piazzi A, Caldera V, et al. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors[J]. J Neurooncol, 2011, 105(2): 345-357.
[24]
Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas:predictive or prognostic [J]. Clin Cancer Res, 2011, 17(13): 4588-4599.
[25]
Ducray F, Idbaih A, Wang XW, et al. Predictive and prognostic factors for gliomas[J]. Expert Rev Anticancer Ther, 2011, 11(5): 781-789.
[26]
Shibahara I, Sonoda Y, Kanamori M, et al. IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade Ⅲ gliomas[J/OL]. Int J Clin Oncol, 2011, DOI: 10.1007/s10147-011-0323-2.
[27]
Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study[J]. Cancer Res, 2004, 64(19): 6892-6899.
[28]
Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma[J]. Am J Pathol, 2007, 170(5): 1445-1453.
